Literature DB >> 27266842

Hyperoxia disrupts the intestinal barrier in newborn rats.

Chung-Ming Chen1, Hsiu-Chu Chou2.   

Abstract

Animal studies have demonstrated that neonatal hyperoxia injures the distal small intestine. This study aimed to determine the effects of neonatal hyperoxia exposure on the intestinal morphology and intestinal barrier integrity in newborn rats. Sprague-Dawley rat pups were exposed to either ambient air or hyperoxia. The ambient air and normobaric hyperoxia groups were maintained in room air and 85% O2 for 2weeks, respectively. The rats were euthanized on Postnatal Day 14, and the terminal ileum was collected for histological analyses and oxidative stress measurements. The generation of reactive oxygen species was evaluated by measuring the production of 8-hydroxy-2'-deoxyguanosine (8-OHdG). The expression and localization of epithelial injury markers [intestinal fatty acid binding protein (I-FABP)] and intestinal barrier proteins [occludin and zonula occludens (ZO)-1] were analyzed through immunofluorescence staining and western blotting. The body weight at birth was comparable between the two groups. On Postnatal Day 14, the rats in the hyperoxia group exhibited significantly lower body weight, a higher serum interleukin-6 level, a higher intestinal injury score, higher 8-OHdG and I-FABP expression, and lower occludin and ZO-1 protein expression than did those in the ambient air group. Hyperoxia exposure injured the distal small intestine and disrupted the intestinal barrier in newborn rats. This may be attributable to oxidative stress during the postnatal period.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hyperoxia; Intestinal fatty acid binding protein; Occludin; Zonula occludens

Mesh:

Substances:

Year:  2016        PMID: 27266842     DOI: 10.1016/j.yexmp.2016.06.001

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  8 in total

1.  Surfactant effects on the viability and function of human mesenchymal stem cells: in vitro and in vivo assessment.

Authors:  Chung-Ming Chen; Hsiu-Chu Chou; Willie Lin; Chris Tseng
Journal:  Stem Cell Res Ther       Date:  2017-08-03       Impact factor: 6.832

2.  ADAR1 Alleviates Inflammation in a Murine Sepsis Model via the ADAR1-miR-30a-SOCS3 Axis.

Authors:  Zhou Shangxun; Li Junjie; Zhao Wei; Wang Yutong; Jia Wenyuan; Liu Shanshou; Wang Yanjun; Wang Qianmei; Feng Zhusheng; Yu Chaoping; Zhuang Ran; Yin Wen; Huang Yang
Journal:  Mediators Inflamm       Date:  2020-03-24       Impact factor: 4.711

3.  Can High Average Oxygen Saturation be a Risk Factor for Necrotizing Enterocolitis in VLBW Infants?

Authors:  Ismail Kursad Gokce; Serife Suna Oguz
Journal:  Int J Prev Med       Date:  2019-11-06

4.  Involvement of nuclear factor erythroid 2‑related factor 2 in neonatal intestinal interleukin‑17D expression in hyperoxia.

Authors:  Xuying Liu; Dongyang Zhang; Qing Cai; Dongyan Liu; Siyu Sun
Journal:  Int J Mol Med       Date:  2020-08-07       Impact factor: 4.101

5.  ROS Plays a Role in the Neonatal Rat Intestinal Barrier Damages Induced by Hyperoxia.

Authors:  D Y Liu; W J Lou; D Y Zhang; S Y Sun
Journal:  Biomed Res Int       Date:  2020-12-26       Impact factor: 3.411

Review 6.  Mechanism of Neonatal Intestinal Injury Induced by Hyperoxia Therapy.

Authors:  Tian-Ming Li; Dong-Yan Liu
Journal:  J Immunol Res       Date:  2022-01-12       Impact factor: 4.818

Review 7.  Oxygen toxicity: cellular mechanisms in normobaric hyperoxia.

Authors:  Ricardo Alva; Maha Mirza; Adam Baiton; Lucas Lazuran; Lyuda Samokysh; Ava Bobinski; Cale Cowan; Alvin Jaimon; Dede Obioru; Tala Al Makhoul; Jeffrey A Stuart
Journal:  Cell Biol Toxicol       Date:  2022-09-16       Impact factor: 6.819

8.  Hyperoxia combined with the B-cell antagonist rituximab led to intestinal dysbiosis in neonatal mice.

Authors:  Kun Yang; Ya-Ji Xu; Yan He; Cheng-Xin Duan; Huai-Fu Wang; Wei-Jun Ding
Journal:  Microbiol Immunol       Date:  2022-06-08       Impact factor: 2.962

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.